SuanFarma-Header SuanFarma-Header

X

Find Dermatology Drugs in Phase I/II Clinical Development

Loading...

All Data

Filters Filter
×
FILTER:
filter Country
    filter News Type
      filter Company
        filter Product Type
          filter Deal Size

            Active Filter(s):

            Product Type

            Companies

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Lead Product(s): BEN-2293

            Therapeutic Area: Dermatology Product Name: BEN-2293

            Highest Development Status: Phase I/ Phase II Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable February 11, 2021

            Details:

            BEN-2293 is a selective Pan-Trk antagonist formulated for topical delivery, with a pharmacokinetic profile designed for low systemic exposure to deliver the optimal safety and efficacy profile in the treatment of itch and inflammation associated with Atopic Dermatitis.